Z
ZielBio
Committed to revolutionizing the treatment of cancers utilizing groundbreaking, proprietary technology
About ZielBio
ZielBio is a biotechnology company focused on discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform. The company employs a multidisciplinary approach, leveraging expertise in chemistry, manufacturing, and controls (CMC) to identify novel, high-value disease targets and develop therapeutic interventions. ZielBio's primary market includes oncology, where it aims to increase long-term patient survival rates with its cutting-edge cancer drugs. The business model revolves around research and development (R&D) of monoclonal antibodies and other therapeutic agents, which are then brought to clinical trials and eventually commercialized. Revenue is generated through funding, partnerships, and potential future sales of approved therapies. ZielBio serves patients, healthcare providers, and the broader medical community by delivering hope through innovative treatments.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Charlottesville, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US Department of Health and Human Services
Virginia Innovation Partnership Corporation
Series A1 investor entered at this stage
Morningside Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ZielBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ZielBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.